UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~ Form 6-K

~~Report~~REPORT OF FOREIGN PRIVATE ISSUER ~~of Foreign~~PURSUANT ~~Issuer~~TO RULE 13a-16 OR 15d-16 UNDER THE

~~PURSUANT to~~SECURITIES ~~Rule~~EXCHANGE ~~13a-16~~ACT orOF ~~15d-16 of the Securities Exchange Act of~~ 1934

For the ~~Month~~ month of ~~October~~December, 2007

Commission File Number 0-30860

Axcan Pharma Inc.

(~~Exact Name~~Translation of ~~Registrant~~registrant’s name into English)

597, boul, Laurier, Mont-Saint-Hilaire (~~Quèbec~~Québec), Canada J3H 6C4

(Address of principal executive ~~offices~~office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F o Form 40-F Xx

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No Xx

~~This Form 6-K~~If ~~consists of an October 1, 2007 press release entitled~~ “~~Axcan~~Yes” ~~Licenses~~is ~~Rights To Cx401~~marked, Anindicate ~~Innovative~~the ~~Biological~~file ~~Product~~number Inassigned ~~Development~~to ~~For~~the ~~The Treatment~~registrant ~~Of Perianal~~in ~~Fistulas,~~connection Awith ~~Significant~~Rule ~~Unmet Medical Need”.~~12g3-2(b):

82-

Exhibit No.		Description

99.1		Material Change Report of Axcan Pharma Inc., dated December 4, 2007

–2–

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AXCAN PHARMA INC.

	AXCAN PHARMA INC.

Date: December 4, 2007	By:	/s/ Richard Tarte
	Name:	Richard Tarte
	Title:	Vice President, Corporate Development
		and General Counsel

Date: October 2, 2007	By:	/s/ Richard Tarte
	Name:	Richard Tarte
	Title:	Vice President, Corporate Development
		and General Counsel

–3–

Filing Compare · AXCAN PHARMA INC